David Lewis

WORK HISTORY

EDUCATION

SKILLS

ABOUT DAVID LEWIS

Dr. David A. Lewis is a distinguished figure in the field of inhalation drug delivery and a successful entrepreneur. He holds a B.Sc, M.Sc, and Ph.D, and is a founding director of Oz-UK Limited, 3Di Solutions Limited, and Lewis Jonsen Limited, demonstrating his leadership and vision in the pharmaceutical and technology sectors.His extensive experience in the industry includes founding the Chiesi Research Centre in Chippenham in 2009, where he established and directed cutting-edge research in inhaled therapies. Dr. Lewis was instrumental in the Bath University spinout that led to the establishment of Vectura Limited, a major player in the inhalation sector, early in his career.Dr. Lewis\'s research interests encompass a broad range of topics within aerosol science, including novel formulation strategies for pulmonary and nasal delivery, device design, and the application of predictive models for product performance. He has a significant track record in the development of semi-empirical equations for understanding and controlling MDI performance, enabling efficient formulation design. His work addresses critical aspects of MDI technology, including the transition to environmentally sustainable propellants and the delivery of drugs for both local and systemic effects.Dr. Lewis\'s innovations have led to the development of a significant number of MDI marketed products, including the widely recognized Clenil (Beclometasone dipropionate) and Fostair (Beclometasone dipropionate, Formoterol Fumarate). He has contributed to the scientific literature through peer-reviewed publications and presentations at national and international conferences. His entrepreneurial drive and deep scientific expertise make him a sought-after leader and innovator in the field of inhalation drug delivery.